Oxime K203: a drug candidate for the treatment of tabun intoxication

Lukas Gorecki1,2, Ondrej Soukup1,2, Tomas Kucera1

  • 1Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01, Hradec Králové, Czech Republic.

Archives of Toxicology
|December 20, 2018
PubMed

Insights

The nerve agent antidote K203 shows excellent in vitro efficacy against tabun poisoning but unconvincing in vivo results, limiting its potential as a broad-spectrum drug. It may serve as a backup for existing tabun antidotes.

Area of Science:

  • Toxicology
  • Medicinal Chemistry
  • Pharmacology

Background:

  • Nerve agents are highly toxic chemical weapons with no efficient causal antidotes.
  • Existing reactivators often fail due to insufficient potency or a narrow reactivation profile.
  • K203, a bis-pyridinium reactivator, has shown promise, particularly against tabun poisoning.

Purpose of the Study:

  • To critically review all available literature data on the bis-pyridinium reactivator K203.
  • To assess K203's potential as a drug candidate for organophosphorus poisoning, with a focus on tabun.
  • To evaluate K203's efficacy, safety, and limitations compared to existing treatments.

Main Methods:

  • Comprehensive literature review of in vitro and in vivo studies on K203.
  • Analysis of K203's synthesis accessibility and chemical properties.
  • Molecular docking simulations to understand enzyme-inhibitor interactions.
  • Comparative assessment of K203's toxicity and efficacy against current standards.

Main Results:

  • K203 is easily synthesized and demonstrates excellent in vitro reactivation of tabun-inhibited acetylcholinesterase (AChE).
  • Molecular docking indicates favorable interactions within the AChE active site.
  • In vivo efficacy data for K203 remains unconvincing, and its versatility does not surpass existing oximes.
  • K203's toxicity profile is comparable to clinically used antidotes.

Conclusions:

  • K203 shows significant potential as an anti-tabun agent based on in vitro data.
  • Its in vivo performance and broad-spectrum activity against all nerve agents are currently insufficient.
  • K203 could be considered a backup or alternative to obidoxime and trimedoxime for tabun poisoning treatment.

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
829
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
513
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
714
Preparation of Amines: Reduction of Oximes and Nitro Compounds01:29

Preparation of Amines: Reduction of Oximes and Nitro Compounds

Oximes can be reduced to primary amines using catalytic hydrogenation, hydride reduction, or sodium metal reduction. The reduction of aliphatic and aromatic nitro compounds to primary amines takes place by either catalytic hydrogenation or by using active metals like Fe, Zn, and Sn in the presence of an acid.
Though catalytic hydrogenation can reduce nitrobenzenes, the reduction is nonselective in the presence of other functional groups. For instance, if nitrobenzene contains an aldehyde group,...
4.6K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
486
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
537